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Meconium analysis has an added advan-
tage in that exposure to the toxicants may
occur only in small amounts but repeat-
edly over prolonged periods. Thus, the
analysis of a cumulative, repository
matrix (meconium) compared to an acute
phase matrix (blood), may be more
sensitive in detecting such types of
exposure. Furthermore, meconium repre-
sents fetal tissue and is therefore a direct
measure of fetal exposure to the toxicant
compared to maternal blood or maternal
hair. The latter are indirect measures of
fetal exposure and can be influenced by
the metabolism of the drug/compound by
themother as well as by factors that affect
placental transfer of the compounds.
Different methods have been used to
analyse neurotoxicants in meconium,
although GC-MS (gas chromatography/
mass spectrometry) provides the most
sensitive and specific method of analy-
sis.
5 However, strict criteria for the
identity of compounds have to be used;
otherwise the high specificity of the
method will be compromised. Unless
the molecular ions are detected in the
mass spectrum, the presence of break-
down ion masses alone may not be
sufficient for identity unless specific
ratios of target ion to qualifiers are also
required.
Whether meconium analysis can be
used to determine the timing of xeno-
biotic exposure is a possibility that
merits further investigation.
Theoretically, since meconium is not
normally excreted in utero, serial ana-
lysis of meconium may indicate periods
of xenobiotic exposure during gestation.
This concept has been explored with
illicit drugs in animal and human
studies. In a study of pregnant rats that
were serially exposed to morphine or
cocaine during gestation, the concentra-
tion of the drugs in the pups’ meconium
was significantly correlated to the tim-
ing, duration, and dose of cocaine or
morphine that were administered to the
dams.
8 Similar relationships have also
been clinically reported in infants born
to mothers who have used cocaine and
heroin during pregnancy.
91 0 However,
extrapolation of this observation to
neurotoxicants, specifically for the pes-
ticides, may be premature at the
moment since the toxicants may
undergo different patterns of metabo-
lism and distribution compared to the
drugs of abuse. What is therefore
needed is an animal model or human
circumstance that can study such a
relationship.
A major limitation of meconium
analysis is that meconium is a more
complex and difficult matrix to analyse
compared to blood or urine. Meconium
analysis requires a thorough, prelimin-
ary clean up procedures (e.g. solid phase
extraction) prior to any analytical
assays. This is a critical step, especially
in GC-MS assays, where sensitivity and
specificity are greatly influenced by
background noise (matrix effects). As
previously mentioned, the use of GC-MS
for the analysis and identification of
compounds in meconium must employ
strict criteria for identification since
many materials in meconium may co-
elute with the compounds of interest.
Overall, meconium analysis is a sen-
sitive and powerful technique to detect
fetal exposure to xenobiotics, including
neurotoxicants. The latter is important
because the fetal brain is most vulner-
able to the adverse effects of these
compound due to its rapid state of brain
growth and development during gesta-
tion. Thus, the sensitive detection of
exposure and the amount of exposure
can be helpful in our understanding of
the immediate and long term effects of
these compounds on the newborn
infant and developing child.
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Newborn screening for congenital
toxoplasmosis: feasible, but benefits
are not established
R Gilbert, C Dezateux
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Perspective on the paper by Schmidt et al (see page 661)
T
he report on the Danish newborn
screening programme for congenital
toxoplasmosis in this month’s issue
adds to evidence from similar pro-
grammes across the globe that newborn
screening is feasible.
1–5 Screening for
toxoplasma specific IgM antibodies in
newborn dried blood spots was first
offered in 1988 by the New England
Neonatal Screening Program. Since
then, newborn screening programmes
for congenital toxoplasmosis have been
established in Denmark (in 1992),
1
Poznan, Poland (in 1994),
4 Porto
Alegre, Brazil (in 1995),
6 and Campos
dos Goytazaces, Brazil (in 1999).
7 In
addition, screening studies have been
conducted for a limited period in south-
ern Sweden (1997–98)
8 and Ireland
(2005–07).
9 The estimated birth preva-
lence of congenital toxoplasmosis per
10 000 live births reported by these
programmes ranges from 0.7 in
Sweden
8 and 0.8 in Massachusetts,
3 to
7.1 in Poland,
41 0and in Brazil, 5.4 in the
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2 and 20 in the public
sector.
7 In European cohorts, approxi-
mately 10% of infected children have
retinochoroiditis during infancy, rising
to 16–18% by 4 years old.
11 12 Bilateral
visual impairment is rare, affecting up
to 4% of children with retinochoroidi-
tis.
13 Screening detects between 43% and
85% of infected neonates.
481 4 –17 The very
low false positive rate means that the
probability of congenital toxoplasmosis
in screen positive infants is usually over
25%.
1248
Newborn screening offers an appar-
ently attractive option for preventing
sequelae from congenital toxoplasmosis.
It costs about one tenth as much as
antenatal screening and avoids the
inconvenience of repeated testing dur-
ing pregnancy, the risk associated with
amniocentesis for prenatal diagnosis,
prolonged antibiotic administration
during pregnancy, and termination of
fetuses at very low risk of disability.
18–20
However, far from encouraging adop-
tion of newborn screening, the Danish
report in this issue highlights the lack of
evidence regarding the key criterion for
screening programmes: the need for an
effective treatment.
1
Infants detected by newborn screen-
ing are prescribed treatment to prevent
the occurrence of new retinochoroidal
lesions after birth. Schmidt et al reported
new lesions in only three of 55 infected
children (5%) after 3 months of
pyrimethamine–sulphonamide treat-
ment. Whether more children would
have developed new lesions if they had
not been treated is not at all certain.
There are no randomised treatment
trials in infants and, in cohort studies,
infected infants are almost always trea-
ted. One exception was a cohort study of
antenatal screening in the
Netherlands.
21 Paediatricians could not
be persuaded to treat the 12 infected
children, three of whom had retinochor-
oiditis and one had intracranial calcifi-
cation. At 3 years, the rate of clinical
manifestations did not differ signifi-
cantly from children screened in
France and Austria who were treated
prenatally and for one year after birth,
although the power to detect a differ-
ence was low.
22
Evidence from randomised trials com-
paring anti-toxoplasma treatment with
no treatment or placebo is limited to
adults, most of whom would have
acquired toxoplasmosis after birth.
23 All
three trials were of poor quality. Two
trials showed no evidence for a bene-
ficial effect of treatment. The third, in
Brazilian adults with frequently recur-
ring disease, found that trimethoprim-
sulphamethoxazole reduced the recur-
rence of retinochoroiditis.
24 As toxoplas-
mic retinochoroiditis is more frequent
and severe in Brazil than in Europe,
possibly due to differences in parasite
strain, these findings may not be gen-
eralisable to European infants with
congenital toxoplasmosis.
25 26
Indirect evidence for the effect of
postnatal treatment on retinochoroiditis
comes from cohort studies that exam-
ined the effect of prenatal treatment. No
cohort studies have found that prenatal
treatment significantly reduces retino-
choroiditis in infected infants
27 or in
children followed up to school age
(unpublished data, EMSCOT study, per-
sonal communication, R Gilbert).
11
Prenatal treatment would be expected
to have an impact on the risk of
retinochoroiditis if it is given prior to
encystment of the parasite. The lack of
evidence for a reduction in lesions may
be because treatment is usually given
after cyst formation: transformation of
the infective tachyzoite form of
Toxoplasma gondii into the bradyzoite
form is complete by two weeks after
infection.
28 Bradyzoite cysts are
impermeable to antibiotics but are
thought to break down transiently when
new retinochoroidal lesions develop.
28 29
Uncertainty about the effectiveness of
postnatal treatment is manifest by the
diverse treatment regimens and in some
centres, high rates of loss to follow
up.
27 30 Depending on where congenital
toxoplasmosis is diagnosed, postnatal
prophylactic treatment can be given for
three months (in Denmark), or, in some
French centres, for two years.
27 Yet even
in France, where women require a
record of being offered prenatal screen-
ing for toxoplasmosis in order to qualify
for state maternity benefits,
31 there is
poor adherence to follow up in some
centres,
32 and widely varying approaches
to management.
27 33 34 Pyrimethamine–
sulphonamide has been the mainstay of
postnatal treatment but is associated
with serious adverse effects (mainly
neutropenia) in 14–50% of infants
33 5
(unpublished data, EMSCOT, R
Gilbert). Alternative treatment options
include spiramycin, co-trimoxazole, and
azithromycin, but no comparative data
exist.
36 Of further concern is evidence
that the parents of children diagnosed
with congenital toxoplasmosis are twice
as likely to have high levels of anxiety
when their child is 3–4 years old than
are parents of uninfected children.
37 This
is despite the finding that, on average,
developmental, cognitive, and beha-
vioural outcomes were similar in
infected and uninfected children born
to infected mothers.
37
How should clinicians and policy
makers proceed given the evidence that
newborn screening is feasible, the lack
of clear evidence of benefits, and the
risk of harm? The first step is to
determine the burden of symptomatic
disease due to congenital toxoplasmosis
that might potentially be prevented by
screening and treatment. Newborn
screening studies can provide valuable
information on the incidence of con-
genital toxoplasmosis and have been
used for this purpose in Sweden,
Poznan, Mexico, Denmark, Brazil, and
most recently Ireland.
2–589 However,
setting up a screening programme is
costly and once running, it can be hard
to stop. Other disadvantages include the
need for long term follow up to deter-
mine outcomes, exposure of children to
potential harmful effects of drugs, and
lack of comparative information from
untreated children. A less costly
approach uses active clinical surveil-
lance to identify newly diagnosed chil-
dren with clinically suspected
congenital toxoplasmosis seen by pae-
diatricians, laboratories, or ophthalmol-
ogists. The findings of a UK-wide study
between 2002 and 2004, published on-
line,
38 estimate that approximately six
children with neurological symptoms
due to congenital toxoplasmosis will be
born in the UK each year (700 000
births), 24 with signs of ocular or
neurological disease. However, more
ocular disease occurred in children that
acquired toxoplasmosis after birth than
in those who were infected congenitally;
in adulthood, most ocular toxoplasmosis
would be due to postnatally acquired
infection.
39 40 These findings suggest
that the public health focus should shift
to primary prevention of postnatally
acquired infection.
Another approach to determining the
burden of disease is to test residual
newborn screening dried blood spots.
These have been widely used in other
conditions either on an anonymised
basis, or retrospectively by retrieving
blood spots for children who are symp-
tomatic, and have been shown to be a
valuable resource for biomarkers of
conditions manifest or detectable in
early life. In the UK, codes of practice
for their use have been established by
the UK Newborn Screening Programme
Centre (http://www.newbornscreening-
bloodspot.org.uk/). The difficulty with
this approach for toxoplasmosis is that
additional samples from mother or child
would be needed to confirm toxoplas-
mosis based on a single test of a
newborn blood spot as the predictive
value of the screening test is only about
25%. Attrition due to difficulties in
tracing families, obtaining consent, and
actually finding the blood spot card are
additional obstacles and have limited
the success of this approach to date.
Storage conditions of the filter paper
cards that contain the blood spots need
to be optimal (about 220˚ C) in order to
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ticularly influenced by temperature
(personal communication, Eskild
Petersen).
The UK National Screening
Committee has recommended that
antenatal prenatal screening should
not be introduced, in view of the lack
of evidence for treatment effectiveness,
clinical harms, costs, and difficulties in
implementation.
16 Newborn screening
has not been supported pending infor-
mation on the effectiveness of postnatal
treatment from a randomised controlled
trial. Given the low risk of new lesions
after birth, such a trial would need to be
very large, involving several coun-
tries.
11 3 A trial of postnatal treatment
may be more feasible in Brazil, or other
tropical countries, where the birth pre-
valence of congenital toxoplasmosis and
risk of clinical sequelae are higher.
However, differences in the strain and
virulence of the parasite are likely to
mean its findings would be of limited
relevance to Europe.
For the foreseeable future, decisions
on whether to start, stop, or continue
antenatal or newborn screening will be
made in the context of considerable
uncertainty, as the definitive treatment
trials need to be large and will be
extremely costly. Waiting for evidence
that treatment does not work is unten-
able, as screening should always be
based on positive evidence of benefit.
Currently, there is no clear evidence that
antenatal or neonatal screening is ben-
eficial. Moreover, the fact that screening
has been carried out for decades does
not provide evidence of its value, but
does reflect costs that will be incurred
by stopping screening. To inform deci-
sions now, clinical and cost effective-
ness models can be used to combine
existing evidence from cohort studies
with regional estimates of the burden of
disease to weigh the balance of potential
benefits, harms, and cost effectiveness.
41
In addition, value of information mod-
els can be useful to estimate the cost
effectiveness of further research, taking
into account consequences such as
continuing or dismantling established
programmes.
42 Such analyses are impor-
tant when very large and expensive
trials are being considered and are
particularly relevant to France and
Austria, which operate centrally regu-
lated antenatal screening programmes.
In France, screening costs at least
£50 million per year (for 780 000 births
per annum).
43 A key principle is that
policy makers need to decide whether to
stop or continue screening indepen-
dently of the laboratory services and
clinicians that stand to gain from the
programme. This can be difficult as the
same laboratories may be needed to
provide the clinical data, and, as toxo-
plasmosis is relatively uncommon, to
explain the disease and its manage-
ment. In the UK, screening policies are
reviewed and recommendations made
by the National Screening Committee,
an independent and internationally
recognised group. This independence is
vital, to ensure that testing is not
implemented just because it can be
done, but because there is good evidence
to suggest that the benefits to pregnant
women and their children outweigh the
harms. Further studies are needed to
address this point.
Arch Dis Child 2006;91:629–632.
doi: 10.1136/adc.2006.094870
Authors’ affiliations
......................
R Gilbert, C Dezateux, Centre for
Epidemiology and Biostatistics, Institute of
Child Health, London, UK
Correspondence to: Dr R Gilbert, Centre for
Epidemiology and Biostatistics, Institute of Child
Health, 30 Guilford Street, London WC1N
1EH, UK; r.gilbert@ich.ucl.ac.uk
Competing interests: none declared
REFERENCES
1 Schmidt DR, Hogh B, Andersen O, et al. The
national neonatal screening programme for
congenital toxoplasmosis in Denmark: results from
the initial four years, 1999–2002. Arch Dis Child
2006;91:661–5.
2 Neto EC, Rubin R, Schulte J, et al. Newborn
screening for congenital infectious diseases.
Emerg Infect Dis 2004;10:1068–73.
3 Guerina NG, Hsu HW, Meissner HC, et al.
Neonatal serologic screening and early treatment
for congenital Toxoplasma gondii infection. The
New England Regional Toxoplasma Working
Group. N Engl J Med 1994;330:1858–63.
4 Paul M, Petersen E, Pawlowski ZS, et al. Neonatal
screening for congenital toxoplasmosis in the
Poznan region of Poland by analysis of
Toxoplasma gondii-specific IgM antibodies eluted
from filter paper blood spots. Pediatr Infect Dis J
2000;19:30–6.
5 Vela-Amieva M, Canedo-Solares I, Gutierrez-
Castrellon P, et al. Short report: neonatal
screening pilot study of Toxoplasma gondii
congenital infection in Mexico. Am J Trop Med
Hyg 2005;72:142–4.
6 Neto EC, Anele E, Rubim R, et al. High prevalence
of congenital toxoplasmosis in Brazil estimated in
a 3-year prospective neonatal screening study.
Int J Epidemiol 2000;29:941–7.
7 Petersen E, Pollak A, Reiter-Owona I. Recent
trends in research on congenital toxoplasmosis.
Int J Parasitol 2001;31:115–44.
8 Evengard B, Petterson K, Engman M-L, et al. Low
incidence of toxoplasma infection during
pregnancy and in newborns in Sweden.
Epidemiol Infect 2001;127:121–7.
9 National Newborn Screening Programme
Republic of Ireland. http: www.nnsp.ie/
disorders_tested/toxoplasmosis_02.html. 2006.
10 Paul M, Petersen E, Szczapa J. Prevalence of
congenital Toxoplasma gondii infection among
newborns from the Poznan region of Poland:
validation of a new combined enzyme
immunoassay for Toxoplasma gondii-specific
immunoglobulin A and immunoglobulin M
antibodies. J Clin Microbiol 2001;39:1912–16.
11 Binquet C, Wallon M, Quantin C, et al. Prognostic
factors for the long-term development of ocular
lesions in 327 children with congenital
toxoplasmosis. Epidemiol Infect
2003;131:1157–68.
12 Gras L, Gilbert RE, Ades AE, et al. Effect of
prenatal treatment on the risk of intracranial and
ocular lesions in children with congenital
toxoplasmosis. Int J Epidemiol
2001;30:1309–30.
13 Wallon M, Kodjikian L, Binquet C, et al. Long-
term ocular prognosis in 327 children with
congenital toxoplasmosis. Pediatrics
2004;113:1567–72.
14 Lebech M, Andersen O, Christensen NC, et al.
Feasibility of neonatal screening for toxoplasma
infection in the absence of prenatal treatment.
Lancet 1999;353:1834–7.
15 Naessens A, Jenum PA, Pollak A, et al. Diagnosis
of congenital toxoplasmosis in the neonatal
period: a multicenter evaluation. J Pediatr
1999;135:714–19.
16 Wallon M, Dunn D, Slimani D, et al. Diagnosis of
congenital toxoplasmosis at birth: what is the
value of testing for IgM and IgA? Eur J Pediatr
1999;158:645–9.
17 Pinon JM, Chemla C, Villena I, et al. Early
neonatal diagnosis of congenital toxoplasmosis:
value of comparative enzyme-linked
immunofiltration assay immunological profiles
and anti-Toxoplasma gondii immunoglobulin M
(IgM) or IgA immunocapture and implications for
postnatal therapeutic strategies. J Clin Microbiol
1996;34:579–83.
18 Working Group on Toxoplasma Infection in
Pregnancy. http: rms.nelh.nhs.uk/screening/
viewResource.asp?categoryID=
2009&dg=107&uri=http%3A, and
libraries.nelh.nhs.uk/common/resources/
%3Fid%3D56186. Antenatal and newborn
screening for toxoplasmosis. Antenatal
Subcommittee of the National Screening
Committee. 2001. http://www.nelh.nhs.uk/
screening/antenatal_pps/Toxo_NSC.pdf.
19 Buffolano W, Sagliocca L, Fratta D, et al. Prenatal
toxoplasmosis screening in Campania region,
Italy. Ital J Gynaecol Obstet 1994;6:70–4.
20 Berrebi A, Kobuch WE, Bessieres MH, et al.
Termination of pregnancy for maternal
toxoplasmosis. Lancet 1994;344:36–9.
21 Conyn-van-Spaedonck MAE. Prevention of
congenital toxoplasmosis in the Netherlands
(thesis). National Institute of Public Health and
Environmental Protection (Netherlands), ISBN 90-
9004179-6, 1991.
22 Gilbert R, Dunn D, Wallon M, et al. Ecological
comparison of the risks of mother-to-child
transmission and clinical manifestations of
congenital toxoplasmosis according to prenatal
treatment protocol. Epidemiol Infect
2001;127:113–20.
23 Gilbert RE, See SE, Jones LV, et al. Antibiotics for
treating and preventing toxoplasma
retinochoroiditis. The Cochrane Library,
2002;issue 3.
24 Silveira C, Belfort R Jr, Muccioli C, et al. The effect
of long-term intermittent trimethoprim/
sulfamethoxazole treatment on recurrences of
toxoplasmic retinochoroiditis. Am J Ophthalmol
2002;134:41–6.
25 Holland GN. Ocular toxoplasmosis: a global
reassessment. Part II: disease manifestations and
management. Am J Ophthalmol 2004;137:1–17.
26 Ajzenberg D, Banuls AL, Su C, et al. Genetic
diversity, clonality and sexuality in Toxoplasma
gondii. Int J Parasitol 2004;34:1185–96.
27 Gras L, Wallon M, Pollak A, et al. Association
between prenatal treatment and clinical
manifestations of congenital toxoplasmosis in
infancy: a cohort study in 13 European centers.
Acta Paediatr Scand 2005;94:1–12.
28 Denkers EY, Gazzinelli RT. Regulation and
function of T-cell-mediated immunity during
Toxoplasma gondii infection. Clin Microbiol Rev
1998;11:569–88.
29 Roberts F, Mets MB, Ferguson DJ, et al.
Histopathological features of ocular
toxoplasmosis in the fetus and infant. Arch
Ophthalmol 2001;119:51–8.
30 Hartup C, Johnson JD, Holliman RE. The
investigation of toxoplasma infection associated
with pregnancy. J Infect 1997;35:47–54.
PERSPECTIVES 631
www.archdischild.com
  group.bmj.com  on March 13, 2013 - Published by  adc.bmj.com Downloaded from 31 Thulliez P. Screening programme for congenital
toxoplasmosis in France. Scand J Infect Dis Suppl
1992;84:43–5.
32 Fricker HH, Pelloux H, Muet F, et al. Prenatal
diagnosis of congenital toxoplasmosis:
comparative value of fetal blood and amniotic
fluid using serological techniques and cultures.
Prenatal Diagn 1997;17:831–5.
33 Gilbert R, Gras L. Effect of timing and type of
treatment on the risk of mother to child
transmission of Toxoplasma gondii. BJOG
2003;110:112–20.
34 Binquet C, Wallon M, Metral P, et al.
[Toxoplasmosis seroconversion in pregnant
women. The differing attitudes in France]. Presse
Med 2004;33:775–9.
35 Kieffer F, Thulliez P, Brezin A, et al. Treatment of
subclinical congenital toxoplasmosis by
sulfadiazine and pyrimethamine continuously
during 1 year: apropos of 46 cases. Arch Pediatr
2002;9:7–13.
36 Derouin F, Jacqz-Aigrain E, Thulliez P, et al.
Cotrimoxazole for prenatal treatment of congenital
toxoplasmosis? Parasitol Today 2000;16:254–6.
37 Freeman K, Salt A, Prusa A, et al. Association
between congenital toxoplasmosis and parent-
reported developmental outcomes, concerns and
impairments, in 3 year old children. Biomed
Central Pediatrics 2005;5:23.
38 Gilbert RE, Tan HK, Cliffe S, et al. Symptomatic
toxoplasma infection due to congenital and
postnatally acquired infection. Arch Dis Child (in
press).
39 Gilbert RE, Stanford MR. Is ocular toxoplasmosis
caused by prenatal or postnatal infection?
Br J Ophthalmol 2000;84:224–6.
40 Holland GN. Ocular toxoplasmosis: a global
reassessment. Part I: epidemiology and course
of disease. Am J Ophthalmol
2003;136:973–88.
41 Fenwick E, Claxton K, Sculpher M. Representing
uncertainty: the role of cost-effectiveness
acceptability curves. Health Econ
2001;10:779–87.
42 Claxton K. The irrelevance of inference: a
decision-making approach to the stochastic
evaluation of health care technologies. J Health
Econ 1999;18:341–64.
43 Thulliez P, Romand S. Prenatal screening and
prevention of congenital toxoplasmosis in France.
In: Amboise-Thomas P, Petersen E, eds.
Congenital toxoplasmosis: scientific background,
clinical management and control. Paris: Springer-
Verlag, 2000:293–8.
Clinical Evidence—Call for contributors
Clinical Evidence is a regularly updated evidence-based journal available worldwide both as
a paper version and on the internet. Clinical Evidence needs to recruit a number of new
contributors. Contributors are healthcare professionals or epidemiologists with experience in
evidence-based medicine and the ability to write in a concise and structured way.
Areas for which we are currently seeking contributors:
N Pregnancy and childbirth
N Endocrine disorders
N Palliative care
N Tropical diseases
We are also looking for contributors for existing topics. For full details on what these topics
are please visit www.clinicalevidence.com/ceweb/contribute/index.jsp
However, we are always looking for others, so do not let this list discourage you.
Being a contributor involves:
N Selecting from a validated, screened search (performed by in-house Information
Specialists) epidemiologically sound studies for inclusion.
N Documenting your decisions about which studies to include on an inclusion and exclusion
form, which we keep on file.
N Writing the text to a highly structured template (about 1500-3000 words), using evidence
from the final studies chosen, within 8-10 weeks of receiving the literature search.
N Working with Clinical Evidence editors to ensure that the final text meets epidemiological
and style standards.
N Updating the text every 12 months using any new, sound evidence that becomes available.
The Clinical Evidence in-house team will conduct the searches for contributors; your task is
simply to filter out high quality studies and incorporate them in the existing text.
If you would like to become a contributor for Clinical Evidence or require more information
about what this involves please send your contact details and a copy of your CV, clearly
stating the clinical area you are interested in, to CECommissioning@bmjgroup.com.
Call for peer reviewers
Clinical Evidence also needs to recruit a number of new peer reviewers specifically with an
interest in the clinical areas stated above, and also others related to general practice. Peer
reviewers are healthcare professionals or epidemiologists with experience in evidence-based
medicine. As a peer reviewer you would be asked for your views on the clinical relevance,
validity, and accessibility of specific topics within the journal, and their usefulness to the
intended audience (international generalists and healthcare professionals, possibly with
limited statistical knowledge). Topics are usually 1500-3000 words in length and we would
ask you to review between 2-5 topics per year. The peer review process takes place
throughout the year, and out turnaround time for each review is ideally 10-14 days.
If you are interested in becoming a peer reviewer for Clinical Evidence, please complete the
peer review questionnaire at www.clinicalevidence.com/ceweb/contribute/peerreviewer.jsp
632 PERSPECTIVES
www.archdischild.com
  group.bmj.com  on March 13, 2013 - Published by  adc.bmj.com Downloaded from doi: 10.1136/adc.2006.094870
 2006 91: 629-631 Arch Dis Child
 
R Gilbert and C Dezateux
 
established
toxoplasmosis: feasible, but benefits are not 
Newborn screening for congenital
  http://adc.bmj.com/content/91/8/629.full.html
Updated information and services can be found at: 
These include:
References
  http://adc.bmj.com/content/91/8/629.full.html#related-urls
Article cited in: 
 
  http://adc.bmj.com/content/91/8/629.full.html#ref-list-1
This article cites 34 articles, 9 of which can be accessed free at:
service
Email alerting
box at the top right corner of the online article.
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic
 (510 articles) Reproductive medicine     
 (236 articles) Pregnancy     
 (1167 articles) Immunology (including allergy)     
 (477 articles) Drugs: infectious diseases     
 (166 articles) Disability     
 (17 articles) Ethics of reproduction     
 (924 articles) Epidemiologic studies     
 (70 articles) Tropical medicine (infectious diseases)     
 (56 articles) Travel medicine     
 (176 articles) Infection (neurology)     
 (297 articles) Screening (public health)     
 (297 articles) Screening (epidemiology)     
 
Articles on similar topics can be found in the following collections
  http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
  http://journals.bmj.com/cgi/reprintform
To order reprints go to:
  http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
  group.bmj.com  on March 13, 2013 - Published by  adc.bmj.com Downloaded from Notes
  http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
  http://journals.bmj.com/cgi/reprintform
To order reprints go to:
  http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
  group.bmj.com  on March 13, 2013 - Published by  adc.bmj.com Downloaded from 